非ステロイド性抗炎症薬の市場規模、シェア＆動向分析レポート：適応症別（関節炎、片頭痛、眼科疾患）、投与経路別、流通チャネル別、地域別、セグメント別予測、2022年～2030年

非ステロイド性抗炎症薬の市場成長・動向

Grand View Research, Inc.の新しいレポートによると、世界の非ステロイド性抗炎症薬市場は、予測期間中にCAGR 5.36%で拡大し、2030年までに312億9000万米ドルに達すると予測されています。

非ステロイド性抗炎症薬は、主に炎症や痛みを和らげたり、上昇した体温を下げたりするために使用される薬です。生理痛、頭痛、発熱、関節炎、捻挫、緊張、その他の慢性疼痛の症状緩和を目的とした非ステロイド性抗炎症薬（NSAIDs）の高い処方率は、予測期間中の市場を牽引すると考えられています。

非ステロイド性抗炎症薬市場は、世界中で標的疾患や慢性疼痛の有病率が上昇していること、また、これらの疾患が老年人口に多く見られることなどの要因から、成長の機会を示すと予想されます。さらに、OTC非ステロイド性抗炎症薬に対する需要の増加や、頭痛、偏頭痛、月経痛に対する非ステロイド性抗炎症薬の採用の増加も、予測期間中の成長を後押しするものと思われます。

さらに、関節炎やその他の疼痛関連疾患の有病率の増加も、成長を支える要因になると考えられています。例えば、変形性関節症の有病率は、欧州地域の他の国々と比較して、英国、フランス、ドイツで高くなっています。関節炎の有病率は、身体活動をよくする人ほど低く、その有病率は年齢とともに上昇すると見られています。したがって、関節炎の有病率の上昇は、予測期間中の成長に貢献することも期待されます。

主要な市場参加者は、世界中で市場シェアを拡大するために、地理的拡大や非ステロイド性抗炎症薬の配合剤の導入などの戦略的イニシアチブを採用しています。また、疼痛管理やその他の炎症性疾患に対する一般用医薬品の承認が増加していることも、予測期間中の成長を後押しするものと思われます。このように、主要企業が採用するさまざまな戦略によって、市場は成長を後押しするものと思われます。

各地域の政府は、自国における片頭痛や関節炎などの疾病の負担を軽減するために、好ましい取り組みを行っています。例えば、米国国立衛生研究所は、疼痛や炎症性疾患の管理を改善するための研究活動を加速させるため、HEALを開始しました。さらに、Patient-Centered Outcomes Research Instituteは、痛みに対する非オピオイド治療の選択肢を導入するためのイニシアチブを取っています。このような取り組みにより、予測期間中の成長率が高まると期待されています。

非ステロイド性抗炎症薬市場レポートハイライト

2021年、全世界で関節炎の有病率が高いことから、関節炎セグメントがNSAIDs市場を独占した

小売薬局分野が最大のシェアを占め、予測期間中もその優位性を維持すると予想される

アジア太平洋地域は、疼痛および関連疾患の有病率の高さ、患者数の多さ、老年人口の増加などの要因から、予測期間中に最も高いCAGRを記録すると予想される

北米は、関節炎の高い有病率、主要な市場プレイヤーの存在、地域内の研究活動の増加により、2021年の市場を独占していました。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
• 調査手法
• 情報調達
  • 購入したデータベース：
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
• 二次情報一覧
• 略語一覧
• 目的

第2章 エグゼクティブサマリー

• 市場概要

第3章 非ステロイド性抗炎症薬市場の変数、動向、範囲

• 市場力学
  • 市場促進要因分析
    • 高齢者人口の増加
    • 標的疾患の有病率の増加
  • 市場制約分析
    • NSAIDに関連する副作用
• 浸透と成長の見通しのマッピング
• ビジネス環境分析ツール
  • SWOT分析;要因別（政治と法律、経済と技術）
  • ポーターのファイブフォース分析
  • 業界分析- アンソフマトリックス
• 価格分析
• 規制シナリオ

第4章 規制および政治勢力

• 主要な市場参加者別最近の動向と影響分析
  • Heat map analysis
• 会社の分類
  • イノベーター
  • 市場のリーダー
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2021年
• 公開会社
  • 企業の市況分析
    • 市場の差別化要因
• プライベートカンパニー
  • 主要新興企業一覧
• 主要取引と戦略的提携分析
  • 新製品の発売
  • 買収
  • 拡張
  • ライセンシングとパートナーシップ

第5章 非ステロイド性抗炎症薬市場-セグメント分析、疾患別、2018年から2030年（100万米ドル）

• 疾患適応症の市場シェア分析、2021年および2030年（100万米ドル）
• セグメントダッシュボード
• 市場規模と予測、トレンド分析、2018年から2030年（100万米ドル）
  • 関節炎
  • 片頭痛
  • 眼科疾患
  • その他

第6章 非ステロイド性抗炎症薬市場-セグメント分析、投与経路別、2018年から2030年（百万米ドル）

• 投与経路の市場シェア分析、2021年および2030年（100万米ドル）
• セグメントダッシュボード
• 市場規模と予測、トレンド分析、2018年から2030年（USD Million）
  • オーラル
  • 話題の
  • その他

第7章 非ステロイド性抗炎症薬市場-セグメント分析、流通チャネル別、2018年から2030年（百万米ドル）

• 流通チャネルの市場シェア分析、2021年および2030年（100万米ドル）
• セグメントダッシュボード
• 市場規模と予測、トレンド分析、2018年から2030年（USD Million）
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 非ステロイド性抗炎症薬市場-セグメント分析、地域別、2018年から2030年（百万米ドル）

• 地域市場シェア分析、2021年および2030年（100万米ドル）
• 地域市場ダッシュボード
• 北米
  • 米国
• カナダ
• 欧州
  • ドイツ
  • 英国
  • スペイン
  • フランス
  • イタリア
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東とアフリカ
  • 南アフリカ
  • アラブ首長国連邦
  • サウジアラビア

第9章 競争力とベンダー情勢

• 参加者の分類
  • イノベーター
  • 市場のリーダー
• 戦略マッピング
  • この市場でプレーヤーが選択した主要な戦略には、次のものがあります。
    • 新製品の発売
    • 取得
    • 拡張
    • 契約、コラボレーション、パートナーシップ
    • その他（再編、売却、市場浸透）：
• 戦略的枠組み
  • 主要企業の市場シェア分析、2021年
• 企業プロファイル
  • Pfizer Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Bayer AG
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • GSK plc
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Dr. Reddy's Laboratories Ltd
    • 会社概要
    • 財務実績
    • 製品パイプライン
    • 戦略的イニシアチブ
  • Viatris Inc
    • 会社概要
    • 財務実績
    • 製品パイプライン
    • 戦略的イニシアチブ
  • Teva Pharmaceutical Industries Ltd.
    • 会社概要
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Johnson and Johnson Services, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
  • Merck &Co., Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 North America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
• Table 4 North America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 5 North America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 6 U.S. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 7 U.S. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 8 Canada NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 9 Canada NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 10 Europe NSAIDs Market, By Country, 2018 - 2030 (USD Million)
• Table 11 Europe NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 12 Europe NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 13 U.K. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 14 U.K. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 15 Germany NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 16 Germany NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 17 France NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 18 France NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 19 Spain NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 20 Spain NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 21 Italy NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 22 Italy NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 23 Asia Pacific NSAIDs Market, By Country, 2018 - 2030 (USD Million)
• Table 24 Asia Pacific NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 25 Asia Pacific NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 26 Japan NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 27 Japan NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
• Table 28 China NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 29 China NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 30 India NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 31 India NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 32 South Korea NSAIDs Market, By Disease Indication 2018 - 2030 (USD Million)
• Table 33 South Korea NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
• Table 34 Australia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 35 Australia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 Latin America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
• Table 37 Latin America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 38 Latin America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 39 Brazil NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 40 Brazil NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
• Table 41 Mexico NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 42 Mexico NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 43 Argentina NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 44 Argentina NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 45 Middle East & Africa NSAIDs Market, By Country, 2018 - 2030 (USD Million)
• Table 46 Middle East & Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 47 Middle East & Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 48 South Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 49 South Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 50 Saudi Arabia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 51 Saudi Arabia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 52 UAE NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
• Table 53 UAE NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 NSAIDs market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 NSAIDs market snapshot
• Fig. 10 NSAIDs market driver impact
• Fig. 11 NSAIDs market restraint impact
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 SWOT analysis, by a factor (political & legal, economic, and technological)
• Fig. 14 Porter's five forces analysis
• Fig. 15 Ansoff matrix
• Fig. 16 NSAIDs market: Disease indication outlook and key takeaways
• Fig. 17 NSAIDs market: Disease indication movement analysis
• Fig. 18 Disease indication segment dashboard
• Fig. 19 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 NSAIDs market: Route of administration outlook and key takeaways
• Fig. 24 NSAIDs market: Route of administration movement analysis
• Fig. 25 Route of administration segment dashboard
• Fig. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Topical market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 NSAIDs market: Distribution channel outlook and key takeaways
• Fig. 30 NSAIDs market: Distribution channel movement analysis
• Fig. 31 Distribution channel segment dashboard
• Fig. 32 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 NSAIDs market: regional outlook and key takeaways
• Fig. 36 Regional outlook, 2021 & 2030 (USD Million)
• Fig. 37 Regional market dashboard
• Fig. 38 North America
• Fig. 39 North America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 U.S.
• Fig. 41 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Canada
• Fig. 43 Canada market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Europe
• Fig. 45 Europe market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Germany
• Fig. 47 Germany market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 U.K.
• Fig. 49 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Spain
• Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 France
• Fig. 53 France market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Italy
• Fig. 55 Italy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Asia Pacific
• Fig. 57 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 58 Japan
• Fig. 59 Japan market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 60 China
• Fig. 61 China market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 62 India
• Fig. 63 India market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 64 South Korea
• Fig. 65 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 66 Australia
• Fig. 67 Australia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 68 Latin America
• Fig. 69 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Brazil
• Fig. 71 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 72 Mexico
• Fig. 73 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 Argentina
• Fig. 75 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 76 Middle East & Africa
• Fig. 77 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 78 South Africa
• Fig. 79 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 80 UAE
• Fig. 81 UAE market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 82 Saudi Arabia
• Fig. 83 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 84 Participant categorization
• Fig. 85 Strategy mapping
• Fig. 86 Strategic framework
• Fig. 87 Company market share analysis

Non-steroidal Anti-inflammatory Drugs Market Growth & Trends:

The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.

The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.

Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.

Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy's Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.

Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.

Non-steroidal Anti-inflammatory Drugs Market Report Highlights:

• In 2021, the arthritis segment dominated the NSAIDs market owing to the higher prevalence of arthritis across the globe

• The retail pharmacy segment held the largest share and is anticipated to maintain its dominance during the forecast period

• Asia Pacific region is expected to witness the highest CAGR during the forecast period owing to factors such as the high prevalence of pain and related disorders, the high pool of patients, and a rising geriatric population across the region

• North America dominated the market in 2021 due to the higher prevalence of arthritis, the presence of leading market players, and increased research activities within the region

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: commodity flow approach
• 1.7 List of Secondary Sources
• 1.8 List of Abbreviations
• 1.9 Objectives
  • 1.9.1 Objective 1
  • 1.9.2 Objective 2
  • 1.9.3 Objective 3
  • 1.9.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Summary

Chapter 3 Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope

• 3.1 Market Dynamics
  • 3.1.1 Market Driver Analysis
    • 3.1.1.1 Increasing Geriatric Population
    • 3.1.1.2 Increasing Prevalence of Targeted Diseases
  • 3.1.2 Market Restraint Analysis
    • 3.1.2.1 Side-effects Associated with NSAIDs
• 3.2 Penetration and Growth Prospect Mapping
• 3.3 Business Environment Analysis Tools
  • 3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
  • 3.3.2 Porter's Five Forces Analysis
  • 3.3.3 Industry Analysis - Ansoff Matrix
• 3.4 Pricing Analysis
• 3.5 Regulatory Scenario

Chapter 4 Regulatory & Political Forces

• 4.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 4.1.1 Heat map analysis
• 4.2 Company Categorization
  • 4.2.1 Innovators
  • 4.2.2 Market Leaders
• 4.3 Vendor Landscape
  • 4.3.1 List of key distributors and channel partners
  • 4.3.2 Key customers
  • 4.3.3 Key company market share analysis, 2021
• 4.4 Public Companies
  • 4.4.1 Company market position analysis
    • 4.4.1.1 Market Differentiators
• 4.5 Private Companies
  • 4.5.1 List of key emerging companies
• 4.6 Major Deals and Strategic Alliances Analysis
  • 4.6.1 New Product Launch
  • 4.6.2 Acquisitions
  • 4.6.3 Expansion
  • 4.6.4 Licensing and Partnerships

Chapter 5 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Disease indication, 2018 - 2030 (USD Million)

• 5.1 Disease Indication Market Share Analysis, 2021 & 2030 (USD Million)
• 5.2 Segment Dashboard
• 5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030 (USD Million)
  • 5.3.1 Arthritis
    • 5.3.1.1 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.2 Migraine
    • 5.3.2.1 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.3 Ophthalmic Diseases
    • 5.3.3.1 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.4 Others
    • 5.3.4.1 Other market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Route of Administration, 2018 - 2030 (USD Million)

• 6.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
• 6.2 Segment Dashboard
• 6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
  • 6.3.1 Oral
    • 6.3.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.2 Topical
    • 6.3.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.3 Others
    • 6.3.3.1 Other market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

• 7.1 Distribution Channel Market Share Analysis, 2021 & 2030 (USD Million)
• 7.2 Segment Dashboard
• 7.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
  • 7.3.1 Hospital Pharmacy
    • 7.3.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3.2 Retail Pharmacy
    • 7.3.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3.3 Online Pharmacy
    • 7.3.3.1 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 8.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
• 8.2 Regional Market Dashboard
• 8.3 North America
  • 8.3.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.3.2 U.S.
    • 8.3.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
• 8.4 Canada
  • 8.4.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
• 8.5 Europe
  • 8.5.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.2 Germany
    • 8.5.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.3 UK
    • 8.5.3.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.4 Spain
    • 8.5.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.5 France
    • 8.5.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.5.6 Italy
    • 8.5.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
• 8.6 Asia Pacific
  • 8.6.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6.2 Japan
    • 8.6.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6.3 China
    • 8.6.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6.4 India
    • 8.6.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6.5 South Korea
    • 8.6.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6.6 Australia
    • 8.6.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
• 8.7 Latin America
  • 8.7.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7.2 Brazil
    • 8.7.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7.3 Mexico
    • 8.7.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7.4 Argentina
    • 8.7.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 8.8 Middle East & Africa
  • 8.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.8.2 South Africa
    • 8.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.8.3 UAE
    • 8.8.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.8.4 Saudi Arabia
    • 8.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Competitive & Vendor Landscape

• 9.1 Participant Categorization
  • 9.1.1 Innovators
  • 9.1.2 Market Leaders
• 9.2 Strategy Mapping
  • 9.2.1 Key Strategies Chosen by Players in this Market Include:
    • 9.2.1.1 Launch of new products
    • 9.2.1.2 Acquisition
    • 9.2.1.3 Expansion
    • 9.2.1.4 Agreements, collaborations, partnerships
    • 9.2.1.5 Others (realignment, divestment, market penetration):
• 9.3 Strategic Framework
  • 9.3.1 Key Company Market Share Analysis, 2021
• 9.4 Company Profiles
  • 9.4.1 Pfizer Inc.
    • 9.4.1.1 Company overview
    • 9.4.1.2 Financial performance
    • 9.4.1.3 Product benchmarking
    • 9.4.1.4 Strategic initiatives
  • 9.4.2 Bayer AG
    • 9.4.2.1 Company overview
    • 9.4.2.2 Financial performance
    • 9.4.2.3 Product benchmarking
    • 9.4.2.4 Strategic initiatives
  • 9.4.3 GSK plc
    • 9.4.3.1 Company overview
    • 9.4.3.2 Financial performance
    • 9.4.3.3 Product benchmarking
    • 9.4.3.4 Strategic initiatives
  • 9.4.4 Dr. Reddy's Laboratories Ltd
    • 9.4.4.1 Company overview
    • 9.4.4.2 Financial performance
    • 9.4.4.3 Product pipeline
    • 9.4.4.4 Strategic initiatives
  • 9.4.5 Viatris Inc
    • 9.4.5.1 Company overview
    • 9.4.5.2 Financial performance
    • 9.4.5.3 Product pipeline
    • 9.4.5.4 Strategic initiatives
  • 9.4.6 Teva Pharmaceutical Industries Ltd.
    • 9.4.6.1 Company overview
    • 9.4.6.2 Product benchmarking
    • 9.4.6.3 Strategic initiatives
  • 9.4.7 Johnson and Johnson Services, Inc.
    • 9.4.7.1 Company overview
    • 9.4.7.2 Financial performance
    • 9.4.7.3 Product benchmarking
  • 9.4.8 Merck & Co., Inc.
    • 9.4.8.1 Company overview
    • 9.4.8.2 Financial performance
    • 9.4.8.3 Product benchmarking
    • 9.4.8.4 Strategic initiatives